The Worldwide BNP and NT-proBNP Market is Projected to reach USD 2.2 Billion by 2028, at a CAGR of 11.4%

BNP and NT-proBNP Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global BNP and NT-proBNP Market size is expected to reach $2.2 billion by 2028, rising at a market growth of 11.4% CAGR during the forecast period.

The Laboratory Testing segment is showcasing a CAGR of 13.4% during (2022 - 2028). The BNP should be properly implemented in most clinical laboratories as a diagnostic test to help rule out heart failure. NP tests are currently offered on automated devices running in clinical laboratories by the majority of the main diagnostic businesses. However, to reduce the burden of heart attacks and other cardiovascular diseases, there is a greater need for laboratory testing due to the rise in cardiovascular diseases (CVDs).

The Myocardial Infarction segment acquired maximum revenue share in the Global BNP and NT-proBNP Market by Application in 2021 thereby, achieving a market value of $879.9 Million by 2028. The increase in myocardial infarction instances and the incorporation of early detection for fast treatment are responsible for the segment's growth. Early diagnosis of myocardial infarction can help avoid additional heart damage and raise the chances of survival. In addition, the availability of diagnostic assays is anticipated to fuel market demand for BNP and NTproBNP tests.

The North America market dominated the Global BNP and NT-proBNP Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $746 Million by 2028. The Asia Pacific market is exhibiting a CAGR of 12.4% during (2022 - 2028). Additionally, The Europe market would showcase a CAGR of 10.7% during (2022 - 2028).

Full Report: https://www.kbvresearch.com/bnp-and-ntprobnp-market/

The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Siemens AG, Danaher Corporation, Gentian Diagnostics ASA, PerkinElmer, Inc., BioMérieux S.A., Quidel Corporation, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd. (Roche Holding Ltd.), and Scripps Laboratories.

Global BNP and NT-proBNP Market Segmentation

By Location of Testing

• Point of Care Testing
• Laboratory Testing

By Application

• Myocardial Infarction
• Acute Coronary Syndrome (ACS)
• Congestive Heart Failure (CHF)
• Others

By Geography

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
• LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA

Companies Profiled

• Abbott Laboratories
• Siemens AG
• Danaher Corporation
• Gentian Diagnostics ASA
• PerkinElmer, Inc.
• BioMérieux S.A.
• Quidel Corporation
• Bio-Rad Laboratories, Inc.
• F.Hoffmann-La Roche Ltd. (Roche Holding Ltd.)
• Scripps Laboratories

Related Reports:

North America BNP and NT-proBNP Market Size & Forecast, 2028

• March-2023
• 70 Pages

LAMEA BNP and NT-proBNP Market Size & Industry Trends, 2028

• March-2023
• 78 Pages

Europe BNP and NT-proBNP Market Size & Growth Forecast, 2028

• March-2023
• 78 Pages

Asia Pacific BNP and NT-proBNP Market Size & Growth to 2028

• March-2023
• 78 Pages